Related Experiment Video
Updated: Apr 15, 2026
3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
Published on: September 13, 2018
Effects of sunitinib malate on growth of human bladder transitional cell line T24 in vitro
Jin Wen1, Han-zhong Li1, Zhi-gang Ji1
1Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Objective:
To investigate the growth-inhibitory effect of sunitinib malate on human bladder transitional cell carcinoma (TCC) in vitro.
Methods:
Human bladder TCC cell line T24 was cultured and exposed to graded concentrations of sunitinib malate for 72 hours in vitro to determine the sensitivities to drug. Cell viability was measured by MTT assay. Cell apoptotic morphology was observed by fluorescence microscope following DAPI staining. Band expressions of Fas, Fas ligand, poly (ADP-ribose) polymerase (PARP) and β-actin were analyzed by Western blot. Wound healing process of T24 cells exposed to sunitinib malate was assayed.
Results:
Sunitinib malate exerted a concentration-dependent and time-dependent inhibitory effect on the T24 cell lines. Fluorescence microscopy showed that small vacuoles appeared in the nuclei of T24 cells and the vacuoles were bigger with higher drug concentrations. The expressions of Fas ligand and PARP in T24 cells treated with sunitinib malate exhibited a concentration-dependent increase. Moreover sunitinib malate suppressed the wound healing process in a concentration-dependent manner.
Conclusion:
Sunitinib malate exerted marked inhibitory activity against bladder cancer cell line T24.
Insights
Sunitinib malate effectively inhibits human bladder cancer cell growth in vitro. The drug demonstrated a concentration-dependent effect, inducing apoptosis and suppressing cell migration in T24 transitional cell carcinoma cells.
Area of Science:
- Oncology
- Pharmacology
Background:
- Bladder cancer, specifically transitional cell carcinoma (TCC), remains a significant health concern.
- Targeted therapies are crucial for improving treatment outcomes in TCC.
Purpose of the Study:
- To evaluate the in vitro anti-cancer effects of sunitinib malate on human bladder TCC.
- To determine the impact of sunitinib malate on TCC cell viability, apoptosis, and migration.
Main Methods:
- Human bladder TCC cell line (T24) was treated with varying concentrations of sunitinib malate.
- Cell viability assessed using MTT assay.
- Apoptosis markers (Fas, Fas ligand, PARP) and cell morphology analyzed via Western blot and DAPI staining.
- Wound healing assay used to evaluate cell migration.
Main Results:
- Sunitinib malate exhibited concentration- and time-dependent inhibition of T24 cell growth.
- Increased expression of Fas ligand and PARP observed, indicating apoptosis induction.
- Suppression of T24 cell migration was evident in wound healing assays.
- Morphological changes, including nuclear vacuolation, were dose-dependent.
Conclusions:
- Sunitinib malate demonstrates significant in vitro inhibitory activity against the T24 bladder cancer cell line.
- The drug induces apoptosis and impairs cell migration, suggesting therapeutic potential.
